[Form 4] ZEVRA THERAPEUTICS, INC. Insider Trading Activity
Tamara A. Favorito, a director of ZEVRA THERAPEUTICS, INC. (ZVRA), purchased 3,175 shares of the company's common stock on 09/12/2025 at a reported price of $7.7852 per share. After the transaction, Ms. Favorito beneficially owned 3,894 shares. The Form 4 was executed by Timothy J. Sangiovanni as attorney-in-fact and dated 09/16/2025.
- Director purchase disclosed: Tamara A. Favorito acquired 3,175 shares on 09/12/2025 at $7.7852 per share
- Ownership after transaction provided: Reporting person beneficially owned 3,894 shares following the purchase
- Form executed and signed: Filing signed by attorney-in-fact Timothy J. Sangiovanni on 09/16/2025
- None.
Insights
TL;DR: A company director reported a small open-market purchase of 3,175 shares, increasing her beneficial holdings to 3,894 shares.
This Form 4 documents a non-derivative acquisition by a director of ZVRA on 09/12/2025 at $7.7852 per share. The disclosed holding post-transaction is explicitly 3,894 shares. The filing was signed by an attorney-in-fact on 09/16/2025. The disclosure is routine in nature and contains no additional details about transaction purpose, funding source, or broader changes to insider ownership beyond the single line item reported.
TL;DR: Director-level insider made a disclosed purchase; filing appears complete for the reported transaction.
The Form 4 lists the reporter as a director and indicates a direct acquisition (transaction code P) of 3,175 common shares at $7.7852, resulting in 3,894 shares beneficially owned. The form identifies the reporter's address and the attorney-in-fact signature. No amendments, derivative transactions, or joint filers are reported. The disclosure follows Section 16 reporting requirements for the single non-derivative transaction presented.